vs
Celsius Holdings, Inc.（CELH）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Celsius Holdings, Inc.的季度营收约是Royalty Pharma plc的1.2倍（$721.6M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 3.4%，领先31.0%），Celsius Holdings, Inc.同比增速更快（117.2% vs 4.8%），过去两年Celsius Holdings, Inc.的营收复合增速更高（42.4% vs 4.6%）
Celsius Holdings Inc.是美国功能饮品企业，旗下Celsius品牌主打健身饮料、能量饮品系列，产品主打健康定位，公司CEO曾表示这一差异化优势是品牌取得市场成功的核心原因。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
CELH vs RPRX — 直观对比
营收规模更大
CELH
是对方的1.2倍
$622.0M
营收增速更快
CELH
高出112.5%
4.8%
净利率更高
RPRX
高出31.0%
3.4%
两年增速更快
CELH
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $721.6M | $622.0M |
| 净利润 | $24.7M | $214.2M |
| 毛利率 | 47.4% | — |
| 营业利润率 | 3.6% | 62.4% |
| 净利率 | 3.4% | 34.4% |
| 营收同比 | 117.2% | 4.8% |
| 净利润同比 | 231.1% | 2.9% |
| 每股收益（稀释后） | $0.04 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CELHRPRX
| Q4 25 | $721.6M | $622.0M | ||
| Q3 25 | $725.1M | $609.3M | ||
| Q2 25 | $739.3M | $578.7M | ||
| Q1 25 | $329.3M | $568.2M | ||
| Q4 24 | $332.2M | $593.6M | ||
| Q3 24 | $265.7M | $564.7M | ||
| Q2 24 | $402.0M | $537.3M | ||
| Q1 24 | $355.7M | $568.0M |
净利润CELHRPRX
| Q4 25 | $24.7M | $214.2M | ||
| Q3 25 | $-61.0M | $288.2M | ||
| Q2 25 | $99.9M | $30.2M | ||
| Q1 25 | $44.4M | $238.3M | ||
| Q4 24 | $-18.9M | $208.2M | ||
| Q3 24 | $6.4M | $544.0M | ||
| Q2 24 | $79.8M | $102.0M | ||
| Q1 24 | $77.8M | $4.8M |
毛利率CELHRPRX
| Q4 25 | 47.4% | — | ||
| Q3 25 | 51.3% | — | ||
| Q2 25 | 51.5% | — | ||
| Q1 25 | 52.3% | — | ||
| Q4 24 | 50.2% | — | ||
| Q3 24 | 46.0% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | 51.2% | — |
营业利润率CELHRPRX
| Q4 25 | 3.6% | 62.4% | ||
| Q3 25 | -11.0% | 70.1% | ||
| Q2 25 | 19.3% | 36.3% | ||
| Q1 25 | 15.8% | 94.0% | ||
| Q4 24 | -5.6% | 60.9% | ||
| Q3 24 | -1.2% | — | ||
| Q2 24 | 23.4% | 50.2% | ||
| Q1 24 | 23.4% | -13.0% |
净利率CELHRPRX
| Q4 25 | 3.4% | 34.4% | ||
| Q3 25 | -8.4% | 47.3% | ||
| Q2 25 | 13.5% | 5.2% | ||
| Q1 25 | 13.5% | 41.9% | ||
| Q4 24 | -5.7% | 35.1% | ||
| Q3 24 | 2.4% | 96.3% | ||
| Q2 24 | 19.8% | 19.0% | ||
| Q1 24 | 21.9% | 0.8% |
每股收益（稀释后）CELHRPRX
| Q4 25 | $0.04 | $0.49 | ||
| Q3 25 | $-0.27 | $0.67 | ||
| Q2 25 | $0.33 | $0.07 | ||
| Q1 25 | $0.15 | $0.55 | ||
| Q4 24 | $-0.10 | $0.46 | ||
| Q3 24 | $0.00 | $1.21 | ||
| Q2 24 | $0.28 | $0.23 | ||
| Q1 24 | $0.27 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $398.9M | $618.7M |
| 总债务越低越好 | $676.9M | $9.0B |
| 股东权益账面价值 | $1.2B | $9.7B |
| 总资产 | $5.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.57× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资CELHRPRX
| Q4 25 | $398.9M | $618.7M | ||
| Q3 25 | $806.0M | $938.9M | ||
| Q2 25 | $615.2M | $631.9M | ||
| Q1 25 | $977.3M | $1.1B | ||
| Q4 24 | $890.2M | $929.0M | ||
| Q3 24 | $903.7M | $950.1M | ||
| Q2 24 | $903.2M | $1.8B | ||
| Q1 24 | $879.5M | $843.0M |
总债务CELHRPRX
| Q4 25 | $676.9M | $9.0B | ||
| Q3 25 | $870.5M | $8.9B | ||
| Q2 25 | $871.9M | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益CELHRPRX
| Q4 25 | $1.2B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $443.1M | $9.8B | ||
| Q4 24 | $399.9M | $10.3B | ||
| Q3 24 | $423.6M | $10.3B | ||
| Q2 24 | $415.8M | $9.8B | ||
| Q1 24 | $338.2M | $9.9B |
总资产CELHRPRX
| Q4 25 | $5.1B | $19.6B | ||
| Q3 25 | $5.3B | $19.3B | ||
| Q2 25 | $3.8B | $18.3B | ||
| Q1 25 | $1.9B | $17.6B | ||
| Q4 24 | $1.8B | $18.2B | ||
| Q3 24 | $1.7B | $18.0B | ||
| Q2 24 | $1.7B | $17.7B | ||
| Q1 24 | $1.6B | $16.1B |
负债/权益比CELHRPRX
| Q4 25 | 0.57× | 0.92× | ||
| Q3 25 | 0.72× | 0.93× | ||
| Q2 25 | 0.69× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-119.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-130.0M | — |
| 自由现金流率自由现金流/营收 | -18.0% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | -4.83× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $323.4M | — |
8季度趋势，按日历期对齐
经营现金流CELHRPRX
| Q4 25 | $-119.4M | $827.1M | ||
| Q3 25 | $331.8M | $702.6M | ||
| Q2 25 | $43.7M | $364.0M | ||
| Q1 25 | $103.4M | $596.1M | ||
| Q4 24 | $75.7M | $742.5M | ||
| Q3 24 | $12.9M | $703.6M | ||
| Q2 24 | $39.6M | $658.2M | ||
| Q1 24 | $134.6M | $664.6M |
自由现金流CELHRPRX
| Q4 25 | $-130.0M | — | ||
| Q3 25 | $321.5M | — | ||
| Q2 25 | $35.5M | — | ||
| Q1 25 | $96.4M | — | ||
| Q4 24 | $70.3M | — | ||
| Q3 24 | $8.7M | — | ||
| Q2 24 | $30.4M | — | ||
| Q1 24 | $130.1M | — |
自由现金流率CELHRPRX
| Q4 25 | -18.0% | — | ||
| Q3 25 | 44.3% | — | ||
| Q2 25 | 4.8% | — | ||
| Q1 25 | 29.3% | — | ||
| Q4 24 | 21.2% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 7.6% | — | ||
| Q1 24 | 36.6% | — |
资本支出强度CELHRPRX
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.1% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 1.3% | — |
现金转化率CELHRPRX
| Q4 25 | -4.83× | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 0.44× | 12.06× | ||
| Q1 25 | 2.33× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.03× | 1.29× | ||
| Q2 24 | 0.50× | 6.45× | ||
| Q1 24 | 1.73× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CELH
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
